Skip to main content
SpringerLink
Log in

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate the objectivity and comprehensiveness of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor (Draft, REC-TCM-ST) in application of Chinese medicine therapeutic effect in patients with advanced non-small cell lung cancer (NSCLC).

Methods

A retrospective clinical research was used in 104 NSCLC patients in stages of III–IV, 53 cases were in Chinese medicine (CM) group and 51 cases were in Western medicine (WM) group. The therapeutic effect of the two groups was evaluated with both REC-TCM-ST and Response Evaluation Criteria in Solid Tumor (RECIST). Kaplan-Meier method was used to analyze the survival time. Kappa test method was used to test the consistency of the two kinds of evaluation results.

Results

According to REC-TCM-ST, the effective rate on relieving tumor mass in the CM group was significantly lower than that in the WM group (P<0.05), but there was no significant difference in tumor-mass stable rate (P>0.05); the symptom of weakness in the CM group was improved significantly, indicating better therapeutic effect than that in the WM group (P<0.01). Karnofsky score in the CM group was significantly better than that in the WM group (P<0.01). In terms of survival conditions, the median survival time and the survival rate of 6 months, 1 year and 2 years of the CM group were higher than the WM group. The total effective rate was 9.62%, and the total stable rate was 72.12% for 104 cases according to RECIST; while the total effective rate was 34.62%, and the total stable rate was 84.62% according to REC-TCM-ST, thus there were significant differences between the results of the two criteria (P<0.01), and there was also some consistency between them, but not satisfactory.

Conclusions

REC-TCM-ST was used to evaluate the therapeutic effect of CM in the treatment of advanced NSCLC, which shows that its evaluation results can better reflect the advantages and disadvantages of CM, and the effectiveness of CM is more objective and comprehensive than RECIST, so REC-TCM-ST is worthy of further improvement and clinical expansion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yang XZ. Therapeutic effect criterion for integrative treatment of traditional Chinese medicine and western medicine in cancer. J Tradit Chin Med (Chin) 2000;41:688–689.

    Google Scholar 

  2. Lin LZ, Lan SQ, Zhou DH. Trial on the therapeutic effect criterion of traditional Chinese medicine treatment for malignant tumors (solid). New J Tradit Chin Med (Chin) 2001;33:5–6.

    Google Scholar 

  3. Zhang PT. Clinical therapeutic effect criterion of traditional Chinese medicine on cancer. China Cancer (Chin) 1999;8:452–454.

    Google Scholar 

  4. Lin LZ, Lan SQ. Application of the assessment on life quality in the field of traditional Chinese medicine treatment on malignant tumors. J Guangzhou Univ Tradit Chin Med (Chin) 1999;16:158–160.

    Google Scholar 

  5. Lin LZ. Application of life quality in comprehensive therapeutic effect evaluation of traditional Chinese medicine oncology. China Cancer (Chin) 2001;10:80–82.

    Google Scholar 

  6. Zhou DH. Clinical traditional Chinese medicine oncology. Beijing: People’s Health Publishing House; 2003:617,620–622.

    Google Scholar 

  7. Medical Administration of the People’s Republic of China. Treatment specifications for common malignant tumor. Beijing: Chinese Peking Union Medical College Press; 1999:773–781.

    Google Scholar 

  8. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang JJ, Meng Q, Chang W, Wan CH. The research progress and status of therapeutic evaluation for tumortreatment. Chin J Cancer (Chin) 2010;29:250–254.

    Google Scholar 

  10. Qiu M, Ying J, Liu L, Cheng J, Zhang Q, Liu Y. Research of therapeutic evaluation criteria of traditional Chinese medicine for tumor. Shanghai J Tradit Chin Med (Chin) 2012;46:7–10.

    Google Scholar 

  11. Tian JH, Zhu FP, Liu LS, Li HG, Xu L. “People-centered” therapeutic efficacy assessment criteria for Chinese medicine on solid tumor. Shanghai J Tradit Chin Med (Chin) 2012;46:3–6.

    Google Scholar 

  12. Lu DY, Ye XW. Application of QOL evaluation for TCM anticancer. J Anhui Tradit Chin Med (Chin) 2011;30(6):70–72.

    Google Scholar 

  13. FDA. Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims, draft guidance. Health Qual Life Outcomes 2006;4:79.

    Article  Google Scholar 

  14. Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB. Challenges to use of health-re-lated quality of life for Food and Drug Administration approval of anti-cancer products. J Natl Cancer Inst Monogr 2007;37:27–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guangzhou University of Chinese Medicine, Guangzhou, 510006, China

    Nuan-zhu Xue  (薛暖珠)

  2. Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510407, China

    Ruo-ming Fang  (方若鸣) & Li-zhu Lin  (林丽珠)

Authors
  1. Nuan-zhu Xue  (薛暖珠)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruo-ming Fang  (方若鸣)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-zhu Lin  (林丽珠)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-zhu Lin  (林丽珠).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xue, Nz., Fang, Rm. & Lin, Lz. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer. Chin. J. Integr. Med. 20, 910–916 (2014). https://doi.org/10.1007/s11655-014-2022-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-014-2022-0

Keywords

Search

Navigation